Perspectives on Ensifentrine and Its Therapeutic Potential in the Treatment of COPD: Evidence to Date
Muhammad Asad Faruqi,Malik M Khurram S Khan,David M Mannino,Malik Khan,David Mannino
DOI: https://doi.org/10.2147/copd.s385811
2024-01-03
International Journal of COPD
Abstract:Muhammad Asad Faruqi, 1 Malik M Khurram S Khan, 1 David M Mannino 1, 2 1 University of Kentucky College of Medicine, Lexington, KY, USA; 2 COPD Foundation, Miami, FL, USA Correspondence: David M Mannino, Department of Medicine, University of Kentucky College of Medicine, 800 Rose Street, Lexington, KY, 40536, USA, Email Ensifentrine is a novel inhalational phosphodiesterase (PDE)3 and PDE4 inhibitor which improves bronchodilation and decreases inflammatory markers by acting locally on the bronchial tissue, with minimal systemic effects. Both preclinical and clinical trials have demonstrated benefits of this therapy, including improvement in lung function and reduction in exacerbations. This therapy is currently under review by the US Food and Drug Administration with a decision expected in 2024. Keywords: chronic obstructive pulmonary disease, therapy, phosphodiesterase inhibitor Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory disorder of the respiratory system which is characterized by irreversible airflow obstruction, remodeling of the airways and acute exacerbations leading to lung function decline, progressive dyspnea, and cough. 1 Treatment of COPD is aimed towards reducing symptoms like shortness of breath and mucous production, preventing flare-ups, slowing disease progression and improving survival. COPD therapies involve both non-pharmacological and pharmacological interventions. Some patients on maximal therapies, including inhaled bronchodilators and steroids and oral phosphodiesterase 4 (PDE4) inhibitors, can still be symptomatic. Thus, new therapies are needed that can improve lung function and airway inflammation when used in addition to existing therapies. 2,3 In addition, current inhaled therapies may not be tolerated by all patients. Thus, therapies with alternative mechanisms of action are needed. In this article, we review the literature available on ensifentrine, a novel phosphodiesterase inhibitor that has the potential to be an add-on therapy for patients with COPD. Ensifentrine (RPL554) is a novel drug that works by dual inhibition of phosphodiesterase (PDE) 3 and 4 enzymes (PDE3, PDE4) and is designed to be delivered via inhalation. 4 Inhibitors of PDE3 and PDE4 target multiple respiratory functions at the cellular and tissue level (Figure 1). PDE3 regulates cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels in the airway smooth muscles, which mediates bronchial tone. 5 PDE4 regulates cAMP levels in the airway cells associated with inflammation and is involved in activation of these cells. 6 PDE4 inhibitors can also activate the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and improve bronchial epithelial cell ciliary movements. 7 Evidence has recently emerged that dual inhibition of PDE3 and PDE4 enzymes results in a synergistic effect of decreased inflammation and improved bronchodilation as both iso-forms of PDE are expressed in the inflammatory cells and airway smooth muscles. 8,9 This article explores the evidence to date regarding ensifentrine as a novel therapeutic option for the treatment of COPD. Figure 1 Combined inhibition of phosphodiesterase (PDE) 3 and PDE4 has additive and synergistic anti-inflammatory and bronchodilatory effects versus inhibition of either PDE3 or PDE4 alone. Furthermore, it increases mucociliary clearance. In red, the main PDE involved in the activity of the specific cell. With permission, from Current Opinion in Pharmacology. Notes : Reprinted from Current Opinion in Pharmacology, Volume 56, Matera MG, Cazzola M, Page C, Prospects for COPD treatment. pages 74–84, copyright 2021, with permission from Elsevier. 3 Several in vitro and in vivo studies evaluated the effect of PDE3/4 inhibitors on airway smooth muscles and degree of inflammation. One study investigated the effects of ensifentrine (RPL554) on the tone of isolated human airway smooth muscles and its synergistic actions when used in conjunction with other bronchodilators including muscarinic antagonists and beta-adrenergic agonists. The study demonstrated that ensifentrine caused relaxation of the bronchial smooth muscles and had a synergistic effect when used with muscarinic antagonists. 10 Ensifentrine's effect on bronchial epithelial cell cultures obtained from normal and Cystic Fibrosis (CF) patients with F508del genotype has also been evaluated. 11 It stimulates CFTR-dependent chloride ion secretion across bronchial epithelial cells and increases cilia beat frequency in primary human bronchial epithelial cells. It also decreases the production of monocyte chemoattractant protein-1 and granulocyte monocyte colony -Abstract Truncated-
respiratory system